Prognostic factors of locally advanced breast cancer patients in Morocco

Goals: Neoadjuvant chemotherapy is known to be beneficial for down-staging patients with locally advanced breast cancer. Clinical stage, degree of cell differentiation and expression of estrogen/progesterone receptors and HER2-neu are all prognostic factors that may effect survival of patients with locally advanced breast cancer (LABC). The present study was conducted to determine clinical and histologic factors that influence survival in a series of moroccan patients with LABC. Methods: We reviewed respectively a total of 102 patients with locally advanced breast cancer in Hassan II University hospital of Fez Morocco, from January 2009 to December 2013. Treatment consisted of neoadjuvant sequential chemotherapy followed by mastectomy, radiotherapy and hormonotherapy for ER/PR positive tumors. Survival analysis with Kaplan Meier was tested for age, body mass index (BMI), clinical stage, degree of histological differentiation, molecular subtypes (Luminal A, luminal B, HER2 amplified and basal-like). To find the most important influencing factors, significant variables were tested with multivariate Cox regression. Results: Mean age of patients with locally advanced breast cancer was 48.6 years [range30–74 years], most were between 40–60 years old (45.8%), 23.4% (21/102) were stage IIIA and 69.8% (71/102) of tumors were of ductal histologic type. Luminal tumors were the most frequent molecular subtype: 58.4% (67/102). Her2 positivity was found in 19 patients (18.3%) and a moderate histological grade in 61 (50%). 48% (58/102) of patients had a high body mass index (≥30). Median follow up was 31.6 months [10–60]. Tumor characteristics that did influence survival were advanced stage (p < 0.001) and histological grade (p < 0.001), while molecular subtypes had no effect. Conclusion: Clinical stage and degree of histological grade are the most significant prognostic factors for Moroccan locally advanced breast cancer cases, while age, BMI and molecular subtype did not appear impact on our patients' survival.

Référence1733
Année2015
TypeCommunication affichée
Date18/03/15
VilleVienna
PaysAustria
Lien externehttp://www.sciencedirect.com/science/article/pii/S096097761570295X
Disciplines associéesEpidémiologie
AuteurAmaadour L
Auteurs associésBenaicha N, Nejjari C, Fatemi H, Arifi S, Mellas N
DisciplineOncologie Médicale
RevueThe Breast
Référence Revue24:117
Congrès14 th St. Gallen International Breast Cancer Conference Primary Therapy of Early Breast Cancer-18 - 21 March
Lien document